Table 1. Characteristics of 20 patients with multiple myeloma enrolled in a phase II study on liposomal daunorubicin and dexamethasone (DD).

		Number of patients
Total		20
Male patients		10
Age		60 years (range: 40-73)
Myeloma type	Immunoglobulin G	14 (70%)
	Immunoglobulin A	3 (15%)
	Light-chain	3 (15%)
Staging of myeloma	Stage I	None
	Stage II	9 (45%)
	Stage III	11 (55%)
Prior therapy		15 (75%)
β2 microglobulin > 2.5 mg/l before DD protocol		11 (55%)
Creatinine > 2.0 mg/dl before DD protocol		None